A study reveals the cause of blood clots in severe “Corona” cases
In very severe cases of “Covid-19”, inflammation and blood clots appear due to antibodies sent to fight the disease and activate unnecessary platelet activity in the lungs.
A new study published in the journal Blood reveals how the antibodies that our bodies produce to protect against “Covid-19” lead to increased platelet function, which can cause fatal blood clots in severely ill people.
Platelets are small cells in the blood that form clots to stop or prevent bleeding, but when platelets don't work properly, it can lead to serious health problems such as strokes and heart attacks.
The study took antibodies produced to fight the spike protein in the Corona virus, from people with severe infection from “Covid-19”, and cloned them in the laboratory for study.
The team found that the microsaccharides on the surface of these antibodies were different from those of healthy individuals, and when those antibodies cloned in vitro were introduced into blood cells taken from healthy donors, an increase in platelet activity was observed.
The study team also found that it was possible to reduce or stop the platelet response in this way in the laboratory by treating the blood with active ingredients from different drugs known to either inhibit platelet function or immune responses.
The results, according to "Russia Today" and "Medical Express", indicate that it may be possible for drugs currently used to treat immune system problems to reduce or prevent cells from producing an excessive response to platelets.
Professor John Gibbins, director of the Institute for Cardiovascular and Metabolic Research at the University of Reading, said: "So far, we have only hypotheses about why platelets involved in clotting are activated during Covid-19 infection."
"One way to think about what's going on is that the immune response that's designed to protect you from infection in some cases, particularly in the critically ill, actually does more harm.
In this case, antibodies that are produced to stop COVID-19 from spreading in infected cells to stimulate platelet activity that causes blood clotting even though there is no wound to heal.”
"We are particularly excited that our studies of platelets in the laboratory identify important mechanisms that explain how and why dangerous blood clots may occur in critically ill COVID-19 patients, and most importantly, also provide clues about how to prevent this," he continued.
“Early in the COVID-19 pandemic, it was clear that infection triggers an immune response, including blood clotting, and that many Of the severe cases and deaths were associated with that.”
"We haven't yet seen results from the MATIS trial, so we don't yet know how these drugs will work in patients, but hopefully we can prevent the inflammatory response and prevent severe disease and blood clots," he said.
It is exciting to see our collaboration with the University of Reading really supports our theory and provides a solid scientific basis for clinical trials.”
Follow our latest local and sports news and the latest political and economic developments via Google news
:
Corona,
Coagulation